MDGL Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.…
Industry Peers
BiotechnologyKey Statistics
About Madrigal Pharmaceuticals (NASDAQ: MDGL)
›
Madrigal Pharmaceuticals (NASDAQ: MDGL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 915 employees.
The shares were at 396.74 USD on 19 November 2026, down 18.8% over 52 weeks. Its 52-week range is 353.54 USD to 615.00 USD: the price is 35.5% below the high and 12.2% above the low.
Its market capitalisation is 9.22B USD.
Madrigal Pharmaceuticals reports return on equity of -47.8%, an operating margin of -10.7% and revenue up 50.1% year over year.
It holds more cash than debt, a net cash position of 606.75M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 18 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 688.78 USD is 73.6% above the current price. The next earnings report is expected on 18 February 2027.